Female Hypoactive Sexual Desire Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Female Hypoactive Sexual Desire Disorder pipeline market report provides a comprehensive overview of the therapeutics under development for Female Hypoactive Sexual Desire Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects.
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market by Key Targets
In the Female Hypoactive Sexual Desire Disorder pipeline drugs market, the key targets are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, D2 Dopamine Receptor, Melanocortin Receptor 4, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and Sodium Dependent Serotonin Transporter.
Key Targets in the Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market
For more target insights, download a free report sample
Key MoA in the Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market
Androgen Receptor Agonist has the highest share in the Female Hypoactive Sexual Desire Disorder pipeline drugs market. The other key mechanisms of action are cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, D2 Dopamine Receptor Antagonist, Melanocortin Receptor 4 Agonist, and Sodium Dependent Dopamine Transporter Inhibitor.
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Female Hypoactive Sexual Desire Disorder pipeline drug market are Oral, Nasal, Subcutaneous, Sublingual, and Vaginal. Oral has the maximum number of pipeline products.
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market
The key molecule types in the Female Hypoactive Sexual Desire Disorder pipeline drugs market are small molecule, and synthetic peptide. Small molecule has the maximum number of pipeline products.
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market
Some of the major companies in the Female Hypoactive Sexual Desire Disorder pipeline drugs market are Emotional Brain BV, Kuhnil Pharmaceutical Co Ltd, Ovoca Bio Plc, Dare Bioscience Inc, Endoceutics Inc, and Palatin Technologies Inc.
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Female Hypoactive Sexual Desire Disorder Pipeline Drugs Market Overview
Key Targets | Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, D2 Dopamine Receptor, Melanocortin Receptor 4, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and Sodium Dependent Serotonin Transporter |
Key Mechanisms of Action | Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, D2 Dopamine Receptor Antagonist, Melanocortin Receptor 4 Agonist, and Sodium Dependent Dopamine Transporter Inhibitor |
Key Routes of Administration | Oral, Nasal, Subcutaneous, Sublingual, and Vaginal |
Key Molecule Types | small molecule, and synthetic peptide |
Major Companies | Emotional Brain BV, Kuhnil Pharmaceutical Co Ltd, Ovoca Bio Plc, Dare Bioscience Inc, Endoceutics Inc, and Palatin Technologies Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
- The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Emotional Brain BV
Endoceutics Inc
Kuhnil Pharmaceutical Co Ltd
Ovoca Bio Plc
Palatin Technologies Inc
S1 Biopharma Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Female Hypoactive Sexual Desire Disorder pipeline drug market?
In the Female Hypoactive Sexual Desire Disorder pipeline drugs market the key targets are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, D2 Dopamine Receptor, Melanocortin Receptor 4, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and Sodium Dependent Serotonin Transporter.
-
What are the key mechanisms of action in the Female Hypoactive Sexual Desire Disorder pipeline drugs market?
In the Female Hypoactive Sexual Desire Disorder pipeline drugs market the key mechanisms of action are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, D2 Dopamine Receptor Antagonist, Melanocortin Receptor 4 Agonist, and Sodium Dependent Dopamine Transporter Inhibitor.
-
What are the key routes of administration in the Female Hypoactive Sexual Desire Disorder pipeline drugs market?
The key routes of administration in the Female Hypoactive Sexual Desire Disorder pipeline drug market are Oral, Nasal, Subcutaneous, Sublingual, and Vaginal. Oral has the maximum number of pipeline products.
-
What are the key molecule types in the Female Hypoactive Sexual Desire Disorder pipeline drugs market?
The key molecule types in the Female Hypoactive Sexual Desire Disorder pipeline drug market are small molecule, and synthetic peptide.
-
What are the major companies in the Female Hypoactive Sexual Desire Disorder pipeline drugs market?
In the Female Hypoactive Sexual Desire Disorder pipeline drugs market the major companies are Emotional Brain BV, Kuhnil Pharmaceutical Co Ltd, Ovoca Bio Plc, Dare Bioscience Inc, Endoceutics Inc, and Palatin Technologies Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.